Boston Scientific Corporation / Advanced Bionics Corporation

Neuromodulation (Chronic Pain, Sensorineural Hearing Loss, Drug Delivery)

Disease Overview

Neuromodulation devices deliver targeted electrical stimulation or programmable drug delivery to nerves, the spinal cord, brain, or cochlea — used for chronic pain (spinal cord stimulators), severe sensorineural hearing loss (cochlear implants), and intrathecal pain/spasticity drug delivery (programmable pumps). The category is technology-intensive, IP-heavy, and dominated by a handful of device firms.

Competitive Landscape

In 2004, the neuromodulation market was led by Medtronic (Itrel SCS family approved 1984; deep-brain stimulation), with Advanced Neuromodulation Systems (ANS, soon acquired by St. Jude Medical in 2005), Cyberonics (vagus nerve stimulation), and Cochlear Ltd. (cochlear implants) as the principal challengers. Advanced Bionics held two strategic positions: a leading cochlear-implant franchise (HiRes 90K) and the Precision rechargeable spinal-cord stimulator that won FDA approval in 2004 — the first fully rechargeable IPG, a meaningful technology lead over Medtronic's primary-cell platform. Boston Scientific's $740M plus earn-outs purchase intended to diversify beyond cardiovascular stents (its core franchise was under pressure post-Guidant deal) and ride neuromodulation's mid-single-digit growth. The relationship deteriorated post-close into FDA quality issues, two cochlear implant recalls, an Alfred Mann termination dispute, and federal-court litigation. The 2008 unwind paid $1.15B to former AB shareholders, kept the pain business inside Boston Scientific Neuromodulation, and returned cochlear and drug-pump units to AB principals for $150M — a textbook cautionary tale of post-close integration risk in technology-driven medtech M&A.